Geode Capital Management’s Epirus Biopharmaceuticals EPRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q3
– Sell
-82,821
Closed -$37K – 4132
2016
Q2
$37K Hold
82,821
– – ﹤0.01% 3974
2016
Q1
$222K Sell
82,821
-111
-0.1% -$312 ﹤0.01% 3599
2015
Q4
$256K Buy
82,932
+222
+0.3% +$1K ﹤0.01% 3583
2015
Q3
$365K Buy
82,710
+7,763
+10% +$45.6K ﹤0.01% 3379
2015
Q2
$427K Buy
74,947
+10,708
+17% +$73.1K ﹤0.01% 3272
2015
Q1
$574K Buy
64,239
+43,456
+209% +$349K ﹤0.01% 3141
2014
Q4
$117K Hold
20,783
– – ﹤0.01% 3752
2014
Q3
$149K Buy
+20,783
New +$180K ﹤0.01% 3657

Other funds holding EPRS

Geode Capital Management's EPRS Position: Q3 2016 in Review

Geode Capital Management sold out of Epirus Biopharmaceuticals (EPRS) in Q3 2016, closing a stake of 82,821 shares — an estimated $37K sold.

Geode Capital Management first reported a position in EPRS in Q3 2014 and held it in 8 quarters. The position peaked at $574K in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

  • Geode Capital Management reported no remaining Epirus Biopharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Geode Capital Management sold 82,821 Epirus Biopharmaceuticals shares in Q3 2016, an estimated $37K.
  • Geode Capital Management first reported a position in Epirus Biopharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Geode Capital Management's Epirus Biopharmaceuticals position peaked at $574K in Q1 2015.
  • 3 funds tracked by Wall St. Rank held Epirus Biopharmaceuticals as of Q3 2016.

Based on Geode Capital Management's 13F filing for Q3 2016, filed 10 Nov 2016.